Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA341283

Local Sample ID:	ID_268
Subject ID:	SU003273
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Gender:	Male and female

Select appropriate tab below to view additional metadata details:

All
Subject
Factors
Collection
Treatment
Sample Preparation
Chromatography
Analysis
MS

Treatment:

Treatment ID:	TR003282
Treatment Summary:	Patients were randomly assigned to one of four treatment groups: Group1- chloroquine (CQ) for 3 days + primaquine (PQ) for 14 days (0.50mg/kg/day) concurrently. Group 2 - dihydroartemisinin/piperaquine (DHA/PPQ) for 3 days + PQ for 14 days (0.50mg/kg/day) concurrently, Group 3 - CQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial CQ, and Group 4 - DHA/PPQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial DHA/PPQ.

Treatment ID:

TR003282

Treatment Summary:

Patients were randomly assigned to one of four treatment groups: Group1- chloroquine (CQ) for 3 days + primaquine (PQ) for 14 days (0.50mg/kg/day) concurrently. Group 2 - dihydroartemisinin/piperaquine (DHA/PPQ) for 3 days + PQ for 14 days (0.50mg/kg/day) concurrently, Group 3 - CQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial CQ, and Group 4 - DHA/PPQ for 3 days + PQ for 14 days (0.50mg/kg/day) starting on day 42 after the initial DHA/PPQ.